MX2024008835A - Tratamiento con encefalitis autoinmune con satralizumab. - Google Patents
Tratamiento con encefalitis autoinmune con satralizumab.Info
- Publication number
- MX2024008835A MX2024008835A MX2024008835A MX2024008835A MX2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A MX 2024008835 A MX2024008835 A MX 2024008835A
- Authority
- MX
- Mexico
- Prior art keywords
- encephalitis
- treatment
- lgi1
- nmdar
- satralizumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263300893P | 2022-01-19 | 2022-01-19 | |
| PCT/JP2023/001270 WO2023140269A1 (en) | 2022-01-19 | 2023-01-18 | Treatment of autoimmune encephalitis with satralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008835A true MX2024008835A (es) | 2024-07-25 |
Family
ID=87348849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008835A MX2024008835A (es) | 2022-01-19 | 2023-01-18 | Tratamiento con encefalitis autoinmune con satralizumab. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250127891A1 (https=) |
| EP (1) | EP4466018A4 (https=) |
| JP (1) | JP2025502891A (https=) |
| KR (1) | KR20240145472A (https=) |
| CN (1) | CN118900699A (https=) |
| AU (1) | AU2023209259A1 (https=) |
| CA (1) | CA3243067A1 (https=) |
| IL (1) | IL314213A (https=) |
| MX (1) | MX2024008835A (https=) |
| TW (1) | TW202337495A (https=) |
| WO (1) | WO2023140269A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| EP3957324A4 (en) | 2019-04-17 | 2023-02-08 | Hiroshima University | THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR |
| EP4159236A4 (en) | 2020-05-29 | 2024-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010003329A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6. |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010065116A2 (en) | 2008-12-02 | 2010-06-10 | The Trustees Of The University Of Pennsylvania | The use of il-27-p28 to antagonize il-6 mediated signaling |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| US20220220210A1 (en) * | 2019-03-29 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function |
-
2023
- 2023-01-18 KR KR1020247027265A patent/KR20240145472A/ko active Pending
- 2023-01-18 CN CN202380028068.8A patent/CN118900699A/zh active Pending
- 2023-01-18 MX MX2024008835A patent/MX2024008835A/es unknown
- 2023-01-18 JP JP2024543040A patent/JP2025502891A/ja active Pending
- 2023-01-18 US US18/729,273 patent/US20250127891A1/en active Pending
- 2023-01-18 CA CA3243067A patent/CA3243067A1/en active Pending
- 2023-01-18 EP EP23743263.8A patent/EP4466018A4/en active Pending
- 2023-01-18 IL IL314213A patent/IL314213A/en unknown
- 2023-01-18 AU AU2023209259A patent/AU2023209259A1/en active Pending
- 2023-01-18 TW TW112102365A patent/TW202337495A/zh unknown
- 2023-01-18 WO PCT/JP2023/001270 patent/WO2023140269A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3243067A1 (en) | 2023-07-27 |
| CN118900699A (zh) | 2024-11-05 |
| JP2025502891A (ja) | 2025-01-28 |
| WO2023140269A1 (en) | 2023-07-27 |
| TW202337495A (zh) | 2023-10-01 |
| EP4466018A1 (en) | 2024-11-27 |
| AU2023209259A1 (en) | 2024-07-18 |
| US20250127891A1 (en) | 2025-04-24 |
| KR20240145472A (ko) | 2024-10-07 |
| EP4466018A4 (en) | 2026-03-25 |
| IL314213A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008835A (es) | Tratamiento con encefalitis autoinmune con satralizumab. | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| Fukumoto et al. | HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer | |
| MX2020012905A (es) | Proteínas de unión multiespecíficas y mejoras con estas. | |
| WO2020014460A8 (en) | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF | |
| EP4269594A3 (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| MX2023005313A (es) | Anticuerpos fcrn y metodos de uso de estos. | |
| PH12020500643A1 (en) | Anti-ngf antibodies and methods thereof | |
| MX2021002190A (es) | Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20. | |
| MX2021002750A (es) | Anticuerpos anti-tnfrsf9 y usos de los mismos. | |
| PH12021500031A1 (en) | Anti-il2 receptor gamma antigen-binding proteins | |
| MY192822A (en) | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
| EP4424324A3 (en) | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| MX2018003820A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
| NZ610267A (en) | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use | |
| WO2023109976A3 (zh) | Ox40抗体及其医药用途 | |
| MX2021014439A (es) | Metodos y aparatos para microorganoesferas derivadas de pacientes. | |
| WO2021119370A8 (en) | Cluster gun system | |
| WO2007044033A3 (en) | Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen | |
| SG10201810608VA (en) | Methods and systems for a combined transaction by an assignee on behalf of one or more users | |
| MX2024006393A (es) | Tratamiento de enfermedad desmielinante del sistema nervioso central (snc) con satralizumab. | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| MX2021013427A (es) | Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33. | |
| EP4530296A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| NZ763061A (en) | Anti-ox40 antibodies and uses thereof |